GlobeNewswire by notified

Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease

Share
  • The Elecsys Amyloid Plasma Panel is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
  • The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
  • This minimally invasive blood-based biomarker test can help to streamline a patient's journey, improving access to diagnosis and helping them better plan for the future.

Basel, 19 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® Amyloid Plasma Panel, an innovative new solution to enable Alzheimer’s disease to be detected earlier. The Elecsys Amyloid Plasma Panel test detects and measures Alzheimer’s disease biomarkers in blood plasma to indicate the need for further confirmatory testing for Alzheimer’s disease. Roche is the first in-vitro diagnostics manufacturer to receive this designation for a blood-based biomarker test for Alzheimer’s.

Alzheimer's disease is the most common form of dementia. Dementia affects more than 55 million people worldwide with more than 10 million new cases each year.1 Barriers to early and accurate diagnosis of Alzheimer’s disease exist across the globe – up to 3 out of 4 people living with symptoms of Alzheimer’s disease have not been diagnosed2, and those who have received a diagnosis, on average waited 2.8 years.

"The key to transforming the life of people with Alzheimer’s disease is to diagnose as early as possible and intervene with the right care plans,” said Thomas Schinecker, CEO of Roche Diagnostics. "Our new diagnostics test has the potential to streamline a patient's journey, improving speed and access toward a confirmatory diagnosis, giving people with Alzheimer’s disease and their caregivers more time to plan and prepare for the future.”

Currently, the diagnosis of Alzheimer’s disease is largely based on clinical symptoms, including cognitive assessment, with a significant number of patients diagnosed when their disease has already advanced. The Elecsys Amyloid Plasma Panel will be the first qualitative test that combines the result of the phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human plasma. Elevations in pTau occur in early stages of Alzheimer’s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer’s disease. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.

The Elecsys Amyloid Plasma Panel has thus the potential to ensure better identification of patients that require further confirmatory testing. This could be done via PET scan or cerebrospinal fluid (CSF) testing, supporting a more timely and accessible diagnosis. In conjunction with other diagnostic tools and the work Roche is doing in developing potential new treatments, this could be an important building-block toward improved care and outcomes for people with Alzheimer’s disease.

Roche has also received a Breakthrough Device Designation for the Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF in vitro diagnostic immunoassays measuring ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of dementia.

About the Elecsys® Amyloid Plasma Panel
The Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau occur in early stages of Alzheimer’s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer’s disease. The result is intended for consideration in conjunction with other clinical information to advise for further confirmatory testing with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.

About Alzheimer's disease
Alzheimer’s is a progressive, fatal disease of the brain that gradually destroys memory, thinking skills and problem solving and impairs daily functioning such as the ability to manage one's own activities. Biological changes are believed to start decades before clinical symptoms of Alzheimer’s become evident. Early signs and symptoms include memory loss, changes in mood or personality, decreased judgement, confusion, and challenges with problem-solving, finding the right word or familiar tasks.

Alzheimer's disease is the most common form of dementia. Dementia affects more than 55 million people worldwide with more than 10 million new cases each year. Up to 3 in 4 people with dementia worldwide have not been diagnosed.

Roche has an extensive Alzheimer’s portfolio, including technology designed to more effectively detect and diagnose Alzheimer’s disease and monitor disease progression and multiple treatment approaches and molecules that may address key pathways of Alzheimer’s disease. Data from two Phase III studies with Roche’s investigational treatment, gantenerumab, in early Alzheimer’s disease are anticipated in November 2022.

About the Breakthrough Device Designation
The Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these medical devices.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] “Dementia.” World Health Organization, World Health Organization, 2 Sept. 2021, https://www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Rates%20of%20dementia,and%20139%20million%20in%202050.
[2] Alzheimer's Disease International. “Adi - over 41 Million Cases of Dementia Go Undiagnosed across the Globe – World Alzheimer Report Reveals.” Alzheimer's Disease International (ADI), 21 Sept. 2021, https://www.alzint.org/news-events/news/over-41-million-cases-of-dementia-go-undiagnosed-across-the-globe-world-alzheimer-report-reveals/.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 61 687 41 47

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 79 771 05 25
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Sileia Urech
Phone: +41 79 935 81 48

Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com

Investor Relations North America


Loren Kalm

Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

GOGL - Invitation to presentation of Q2 2022 Results17.8.2022 19:30:59 CEST | Press release

Golden Ocean Group Limited (the “Company) will publish its financial results for the second quarter of 2022 on Thursday August 25, 2022. In connection with the release, a conference call and webcast will be held as described below: Conference call and webcast A conference call will be held at 4:00 P.M. CET (10:00 A.M. New York Time) on Thursday August 25, 2022. The presentation will be available for download from the Investor Relations section at www.goldenocean.bm (under "Presentations") prior to the conference call/webcast. In order to listen to the presentation you may do one of the following: a. Webcast Visit the Investor Relations section of the Company’s website at www.goldenocean.bm and click on the link to “Financial Calendar and Webcast”, or access directly via the webcast link below. GOGL Q2 2022 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered. GOGL Q2 2022

Changes in Nokia Corporation's own shares17.8.2022 18:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 17 August 2022 at 19:30 EEST Changes in Nokia Corporation's own shares Espoo, Finland – A total of 189 403 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plan in accordance with the rules of the plan. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plan as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 79 311 737. About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks. We create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs. Adhering to the highest standards of integrity and security, w

Spryker Recognized as a Visionary in 2022 Magic Quadrant™ For Digital Commerce17.8.2022 18:00:00 CEST | Press release

BERLIN and NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Spryker, a leading digital commerce platform for Sophisticated Commerce use cases in B2B, Enterprise Marketplaces, IoT and Unified Commerce, has been recognized by Gartner® as a Visionary in the 2022 Magic Quadrant™ for Digital Commerce. It is Spryker's third consecutive inclusion in the Gartner® Magic Quadrant™ for Digital Commerce. “At Spryker, our goal is to enable digital innovation and differentiation with our composable platform designed specifically for sophisticated transactional business models. We believe being recognized for the second time as a Visionary validates our continued dedication to empowering companies to grow, innovate, and differentiate,” said Boris Lokschin, Co-Founder and CEO at Spryker. “This year we launched our App Composition Platform as the latest stage in our commitment to delivering true composability. This first of its kind platform is why we feel Spryker continues to be recognized in the market. W

Nextensa NV/SA : Half-Year Financial Report 202217.8.2022 17:40:00 CEST | Press release

HALF-YEAR FINANCIAL REPORT 2022 Regulated information Brussels, 17 August 2022 5:40 PM CEST For the first half-year of the financial year 2022 we record the following key data: • The rental income increased by € 3.0 million compared to June last year and now amounts to € 33.2 million • The financial debt ratio has decreased from 48.56% at the end of 2021 to 46.31% on 30 June 2022, in line with the predefined plan • The occupancy rate increased and is now 90.30% compared to 89.09% at the end of 2021 • The extension of the Shopping center Knauf Schmiede welcomes its first shops • The Park Lane phase II project at Tour & Taxis has been launched with a successful reservation of 50% of the apartments of the first section • The construction works on The Emerald office building (7,000 m2) started on Cloche d’Or, a new urban district in the southern outskirts of Luxembourg City Attachment SEMI-AR_2022_ENG_final

Matthews International Acquires OLBRICH GmbH and R+S Automotive GmbH, Extends Engineering Capabilities for Energy17.8.2022 14:49:41 CEST | Press release

PITTSBURGH, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Matthews International Corporation (NASDAQ GSM: MATW) announced today that the Company has closed on the previously-announced acquisitions of German based engineering firms, OLBRICH GmbH (“OLBRICH”) and R+S Automotive GmbH (“R+S Automotive”), for EUR €43 million (approximately U.S. $45 million). Headquartered in Bocholt, Germany, OLBRICH is a production and intelligent equipment manufacturer, specializing in purpose-built rotary processing equipment, including equipment used in the manufacturing of dry and wet electrodes for lithium-ion batteries uses in electric vehicles and components for hydrogen fuel cells and electrolyzers, with additional strong positions in Specialty & Pharma, Packaging and Home & Décor. R+S Automotive is a specialty engineering services provider of automation, plant and tooling concepts for automotive manufacturing companies around the world. The Company plans to integrate OLBRICH and R+S Automotive with its Saueres